Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: AIDS Vaccine 2009

Open Access Open Badges Poster presentation

P02-04. Multimeric soluble CD40 ligand efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus strains

J Najera*, C Gomez and M Esteban

  • * Corresponding author: J Najera

Author Affiliations

Molecular and Cellular Biology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain

For all author emails, please log on.

Retrovirology 2009, 6(Suppl 3):P9  doi:10.1186/1742-4690-6-S3-P9

The electronic version of this article is the complete one and can be found online at:

Published:22 October 2009

© 2009 Najera et al; licensee BioMed Central Ltd.


The attenuated poxvirus vectors MVA and NYVAC are now in clinical trials against HIV/AIDS. Due to the vectors restricted replication capacity in human cells, approaches to enhance their immunogenicity are highly desirable.


Here, we have analyzed the ability of a soluble form of hexameric CD40L (sCD40L) to stimulate specific immune responses to HIV antigens when inoculated in mice during priming with DNA and in the booster with MVA or NYVAC, expressing the vectors HIV-1 Env, Gag, Pol and Nef antigens from clade B.


Our findings revealed that sCD40L in DNA/poxvirus combination enhanced the magnitude about 2-fold (DNA-B/MVA-B) and 4-fold (DNA-B/NYVAC-B), as well as the breath of the HIV antigen specific cellular immune responses. sCD40L was necessary in both prime and boost inoculations triggering a potent polarization of the the response towards a Th1 type. In DNA-B/NYVAC-B regime the addition of sCD40L significantly enhanced the humoral immune response against HIV gp160, but not in DNA-B/MVA-B combination.


These findings provided evidence for the immunostimulatory benefit od sCD40L when DNA and the poxvirus vectors MVA and NYVAC are used as immunogens.